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Development of the PraziCalc mobile device-app to calculate 
praziquantel dosage in the treatment of schistosomiasis
Dear Editor
Schistosomiasis is an infectious disease caused by trematode parasites of the 
genus Schistosoma. According to the World Health Organization (WHO), at least 
206.5 million people required preventive treatment, of which more than 88 million 
people were reported to have been treated1. Currently, three drugs are used for 
the treatment of schistosomiasis: praziquantel, metrifonate, and oxamniquine. All 
three have a history of success at the individual clinical level and in population or 
community-based chemotherapy2. However, praziquantel remains the drug of choice 
in humans because of its high efficacy, low toxicity, and affordability. Currently, 
large-scale administration of praziquantel (PZQ) is the main measure for controlling 
schistosomiasis, as recommended by WHO focusing on morbidity control3. 
According to WHO, praziquantel is available in 600 mg tablets and must be 
administered orally in a single dose of 40 mg/kg of body weight after a meal3. In 
some countries like Brazil, the Ministry of Health has its own guidelines. In this 
country, the praziquantel dose is given according to the age group: children up 
to 15 years old (60 mg/kg) and adults (50 mg/kg) of body weight4. Determining 
the treatment dosage by body weight using scales in a global preventive program 
is considered problematic due to a substantial risk of technical and systematic 
measurement errors5. In endemic areas, mainly in Africa, in order to facilitate 
treatment delivery, WHO recommends to administer praziquantel using a dose-pole, 
calculating the appropriate dosage by height instead of weight6. Studies have shown 
that height assessment rather than weighing scale in the treatment of schistosomiasis 
using the dose pole is promising6,7. However, praziquantel must be administered 
between an acceptable dosage (30-60 mg/kg) and an ideal dosage (40-60 mg/kg). 
The under dosing of the drug could result in a partial or inadequate treatment, as 
much as an over dosage could result in side-effects such as abdominal pain, nausea 
and headache6,7. The dose-pole use is based on the individual height and does not 
take into account individuals of the same height with different body weight. Baan 
et al.8 has shown, in African girls, that the use of the WHO pole dose is inaccurate 
in dosing the appropriate amount of praziquantel in overweight/obese girls. Thus, 
despite the dose-pole benefits particularly in a poor resource scenario, following 
a regimen of exposures to increasing amounts of PZQ, the development of a more 
accurate and straightforward method for calculating the optimal dose to reduce the 
error of weight-based treatment is urgently needed. Treatment performed in a large 
number of patients in areas where the drug is still administered based on weight, such 
as in Brazil, there is a grueling job of calculating adequate praziquantel dosing based 
on the individual’s weight. Thus, we present a mobile device-app called PraziCalc 
which facilitates and automatically calculates the optimal dosage of praziquantel 
based on the patient’s body weight, ensuring the effectiveness oftreatment and the 
recommended dosage.
The app system
We have developed a mobile-device app to simplify the calculation of 
praziquantel dosage. The system is easy to use by any health worker, teacher, 
Viana et al.
Rev Inst Med Trop São Paulo. 2018;60:e42Page 2 of 3
community volunteeror drug distributor and it only 
requires a mobile device (e.g. smartphone, tablet etc.). 
The app was created in 2017, it is free to all users, 
bilingual (English/Portuguese) and available for iOS and 
android operational systems. The app works as it follows: 
firstly, there is an initial screen where it is possible to 
choose if the drug will be administrated according to the 
guidelines of the World Health Organization (WHO) or 
the Health Ministry of Brazil (step 1). According to WHO, 
praziquantel, which is available in 600 mg tablets, should 
be administered orally in a single dose of 40 mg/kg of 
body weight3. In Brazil, the Ministry of Health has its own 
guideline. Praziquantel dosage is prescribed according to 
the age group (children up to 15 years old or adult - step 2) 
and body weight of the individual and administered orally 
in a single dose of 50 mg/kg for adults and 60 mg/kg for 
children after a meal4. Subsequently, it is possible to entry 
the individual weight (step 3) and, through a calculation 
(P x D / 600, where P is the weight and D is the dosage in 
mg of the drug), the recommended amount of tablets that 
should be administered to each patient (step 4) is informed. 
Figure 1 summarizes the steps to use the PraziCalc app. 
CONCLUSIONS
Through the use of this innovative mobile device-app, 
many benefits mau occur for research in this area and for 
the infected population. Our purpose is to publicize and 
make the PraziCalc app accessible to any health center 
that treats the disease with praziquantel, facilitating the 
incorporation of this treatment process directed to patients 
with schistosomiasis in endemic areas, who need preventive 
chemotherapy, in medical clinics and in health centers. We 
believe this tool will assist the medical and fieldwork teams 
in presenting a more dynamic, faster and safe method to 
deliver praziquantel in the recommended dosage where the 
drug is still administered based on body weight.
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Figure 1 - Steps to use the PraziCalc mobile device-app: 1) choose if the drug will be administrated according to the guidelines of 
the World Health Organization or the Health Ministry of Brazil; 2) in Brazil, praziquantel dosage is given according to the age group 
(children or adult); 3) entry with the individual weight; 4) recommendation on the amount of tablets that should be administered to 
the patient. Note: The calculation example in the figure was according to WHO guidelines
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